SARS CoV 2 News and Research

RSS

SARS-CoV-2 infection and transmission in the North American deer mouse

A recent study conducted in Canada reports that the North American deer mouse can be infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans.

23 Jun 2021

Repurposing immunomodulatory drugs to treat COVID-19

EULAR has released new points to consider on the use of immunomodulatory drugs in the fight against severe COVID-19.

23 Jun 2021

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Researchers have suggested that repeated vaccination against SARS-CoV-2 may enable previously uninfected individuals to cope with viral variants.

23 Jun 2021

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.

23 Jun 2021

Recovering from critical COVID-19: A secondary analysis of a UK study

A study has aimed to characterize the severity levels of fatigue as a long-lasting symptom post-COVID-19 in patients who were ICU-survivors.

23 Jun 2021

A study on hospitalized COVID-19 patients who received plasma therapy

A new study has been published which focuses on the evaluation of the outcomes of infected COVID-19 patients who were treated with CCP therapy.

23 Jun 2021

Natural compound myricetin shows antiviral potential against SARS-CoV-2

New findings from a team of Chinese researchers suggest natural compounds — specifically the flavonoid myricetin — could also be a potential drug candidate for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

23 Jun 2021

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Researchers found antibody levels in mRNA vaccinated individuals varied with age, gender, and previous coronavirus disease (COVID-19) infection.

23 Jun 2021

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

New research published in the journal Viruses suggests recovering from a coronavirus disease 2019 (COVID-19) infection provides immunity against the B.1.1.7 (or UK) variant. The time when the previous infection took place and the variant involved in prior infection influenced cross-neutralization.

23 Jun 2021

Study shows equitable allocation strategies for SARS-CoV-2 vaccines have a comparative edge

In a recent paper, US researchers demonstrate that equitable distributions of vaccines against COVID-19 are a very optimal approach.

23 Jun 2021

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.

23 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

Genome surveillance tool facilitates detection of COVID-19 variants

Swedish researchers have developed COVseq, a SARS-CoV-2 genome tracker that can be produced at a large scale for a small cost.

23 Jun 2021

Airborne pollen grains facilitate spread of COVID-19 by carrying SARS-CoV-2 particles

Computer models simulating the movement of pollen grains from trees in crowded areas could accelerate the spread of COVID-19.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

The rapid development of safe and efficacious vaccines against SARS-CoV-2 has offered hope that the global COVID-19 pandemic may soon be under control. However, vaccinations remain incomplete in many developed nations, and lag further still in the developing world.

23 Jun 2021

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

As many as 16.8 million Americans had undiagnosed SARS-CoV-2 infections - 5 times the rate of diagnosed infections - by the end of July of 2020, according to an analysis of antibodies from more than 8,000 previously undiagnosed adults collected during the pandemic's first wave.

23 Jun 2021

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, announced today that the U.S. Patent and Trade Office has issued a notice of allowance for the patent application for a novel Surrogate Virus Neutralization Technology (sVNT).

23 Jun 2021

Study provides treatment guidance for children and adolescents with multisystem inflammatory syndrome

An analysis conducted by a group of investigators including Tamara Bradford, MD, Associate Professor of Pediatrics at LSU Health New Orleans School of Medicine, found that children and adolescents with Multisystem inflammatory syndrome in children (MIS-C) initially treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

22 Jun 2021

Molecular study reveals signs of inflammation in brains of people who died of COVID-19

The most comprehensive molecular study to date of the brains of people who died of COVID-19 turned up unmistakable signs of inflammation and impaired brain circuits.

22 Jun 2021

SARS CoV 2 News and Research

SARS-CoV-2 infection and transmission in the North American deer mouse

Repurposing immunomodulatory drugs to treat COVID-19

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Recovering from critical COVID-19: A secondary analysis of a UK study

A study on hospitalized COVID-19 patients who received plasma therapy

Natural compound myricetin shows antiviral potential against SARS-CoV-2

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Study shows equitable allocation strategies for SARS-CoV-2 vaccines have a comparative edge

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Researchers review the origins of SARS-CoV-2 and present treatment methods

Genome surveillance tool facilitates detection of COVID-19 variants

Airborne pollen grains facilitate spread of COVID-19 by carrying SARS-CoV-2 particles

New study enrolls young adults to evaluate SARS-CoV-2 infection

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

Study provides treatment guidance for children and adolescents with multisystem inflammatory syndrome

Molecular study reveals signs of inflammation in brains of people who died of COVID-19

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News